Daily Medication Pearl: Maribavir (Livtencity)
Maribavir (Livtencity) is indicated for the treatment of adults and pediatric patients with post-transplant cytomegalovirus infection.
Medication Pearl of the Day: Maribavir (Livtencity)
Indication: Maribavir (Livtencity) is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients, 12 years of age and older and weighing at least 35 kg, with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. CMV is a genus of viruses in the order Herpesvirales, and is related to the viruses that cause chickenpox and infectious mononucleosis.
- Dosing: 400 mg (two 200 mg tablets) orally twice daily, with or without food.
- Dosage forms: Tablets 200 mg of maribavir.
- Adverse events: The most common adverse events (all grades, >10%) in subjects treated with maribavir were taste disturbance, nausea, diarrhea, vomiting, and fatigue.
- Mechanism of action: The antiviral activity of maribavir is mediated by competitive inhibition of the protein kinase activity of human CMV enzyme pUL97, which results in inhibition of the phosphorylation of proteins.
- Manufacturer: Takeda